Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

The human epidermal growth factor receptor 3 (HER3) has in recent years been recognized as a key node in the complex signaling network of many different cancers. It is implicated in de novo and acquired resistance against therapies targeting other growth factor receptors, e.g., EGFR, HER2, and it is...

Descripción completa

Detalles Bibliográficos
Autores principales: Malm, Magdalena, Frejd, Fredrik Y., Ståhl, Stefan, Löfblom, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058629/
https://www.ncbi.nlm.nih.gov/pubmed/27532938
http://dx.doi.org/10.1080/19420862.2016.1212147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058629/
https://www.ncbi.nlm.nih.gov/pubmed/27532938
http://dx.doi.org/10.1080/19420862.2016.1212147

Ejemplares similares